Sharma A, Gour A, Bhatt S, Rath S, Malik T, Dogra A, et al. Effect of IS01957, a para-coumaric acid derivative on pharmacokinetic modulation of diclofenac through oral route for augmented efficacy. Drug Dev Res. 2019;80:948-957 pubmed publisher

Casadellà M, Manzardo C, Noguera Julian M, Ferrer E, Domingo P, Perez Alvarez S, et al. Clinical value of ultradeep HIV-1 genotyping and tropism testing in late presenters with advanced disease. AIDS. 2015;29:1493-504 pubmed publisher

Ciaffi L, Koulla Shiro S, Sawadogo A, Le Moing V, Eymard Duvernay S, Izard S, et al. Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in Africa. AIDS. 2015;29:1473-81 pubmed publisher

Beumer J, Pillai V, Parise R, Christner S, Kiesel B, Rudek M, et al. Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation. Br J Clin Pharmacol. 2015;80:1097-108 pubmed publisher

He Y, Ho C. Amorphous Solid Dispersions: Utilization and Challenges in Drug Discovery and Development. J Pharm Sci. 2015;104:3237-58 pubmed publisher

Flax V, Adair L, Allen L, Shahab Ferdows S, Hampel D, Chasela C, et al. Plasma Micronutrient Concentrations Are Altered by Antiretroviral Therapy and Lipid-Based Nutrient Supplements in Lactating HIV-Infected Malawian Women. J Nutr. 2015;145:1950-7 pubmed publisher

Ngoma M, Misir A, Mutale W, Rampakakis E, Sampalis J, Elong A, et al. Efficacy of WHO recommendation for continued breastfeeding and maternal cART for prevention of perinatal and postnatal HIV transmission in Zambia. J Int AIDS Soc. 2015;18:19352 pubmed publisher

Dai Z, Ai C, Ge G, He Y, Wu J, Wang J, et al. A Mechanism-Based Model for the Prediction of the Metabolic Sites of Steroids Mediated by Cytochrome P450 3A4. Int J Mol Sci. 2015;16:14677-94 pubmed publisher

Wang X, Hu W, Zhang T, Mao Y, Liu N, Wang S. Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na(+)-dependent taurocholate cotransporting polypeptide activity. Antiviral Res. 2015;120:140-6 pubmed publisher

Sakuma S, Matsumoto S, Ishizuka N, Mohri K, Fukushima M, Ohba C, et al. Enhanced Boosting of Oral Absorption of Lopinavir Through Electrospray Coencapsulation with Ritonavir. J Pharm Sci. 2015;104:2977-85 pubmed publisher

Keemink J, Augustijns P, Annaert P. Unbound ritonavir concentrations in rat and human hepatocytes. J Pharm Sci. 2015;104:2378-87 pubmed publisher

Greenblatt D, Harmatz J. Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies. Br J Clin Pharmacol. 2015;80:342-50 pubmed publisher

Mishra R, Wei C, Hresko R, Bajpai R, Heitmeier M, Matulis S, et al. In Silico Modeling-based Identification of Glucose Transporter 4 (GLUT4)-selective Inhibitors for Cancer Therapy. J Biol Chem. 2015;290:14441-53 pubmed publisher

Ofotokun I, Na L, Landovitz R, Ribaudo H, McComsey G, Godfrey C, et al. Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. Clin Infect Dis. 2015;60:1842-51 pubmed publisher

Amano M, Tojo Y, Salcedo Gómez P, Parham G, Nyalapatla P, Das D, et al. A novel tricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor, GRL-0739, effectively inhibits the replication of multidrug-resistant HIV-1 variants and has a desirable central nervous system penetration property in vitro. Antimicrob Agents Chemother. 2015;59:2625-35 pubmed publisher

Martin T, Plautz S, Pannier A. Temporal endogenous gene expression profiles in response to lipid-mediated transfection. J Gene Med. 2015;17:14-32 pubmed publisher

Salem A, Chiu Y, Valdes J, Nilius A, Klein C. A novel ritonavir paediatric powder formulation is bioequivalent to ritonavir oral solution with a similar food effect. Antivir Ther. 2015;20:425-32 pubmed publisher

Dalva Aydemir S, Bajpai R, Martinez M, Adekola K, Kandela I, Wei C, et al. Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin. Clin Cancer Res. 2015;21:1161-71 pubmed publisher

Santos J, Llibre J, Berrio Galan D, Bravo I, Miranda C, Pérez Alvarez S, et al. Monotherapy with boosted PIs as an ART simplification strategy in clinical practice. J Antimicrob Chemother. 2015;70:1124-9 pubmed publisher

Brennan B, Poirier A, Moreira S, Morcos P, Goelzer P, Portmann R, et al. Characterization of the transmembrane transport and absolute bioavailability of the HCV protease inhibitor danoprevir. Clin Pharmacokinet. 2015;54:537-49 pubmed publisher

Sprenger H, Langebeek N, Mulder P, Ten Napel C, Vriesendorp R, Hoepelman A, et al. A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study. HIV Med. 2015;16:122-31 pubmed publisher

Sangenito L, Menna Barreto R, D Ávila Levy C, Santos A, Branquinha M. Decoding the anti-Trypanosoma cruzi action of HIV peptidase inhibitors using epimastigotes as a model. PLoS ONE. 2014;9:e113957 pubmed publisher

Jager N, Rosing H, Schellens J, Beijnen J. Procedures and practices for the validation of bioanalytical methods using dried blood spots: a review. Bioanalysis. 2014;6:2481-514 pubmed publisher

Kawakami K. Surface effects on the crystallization of ritonavir glass. J Pharm Sci. 2015;104:276-9 pubmed publisher

Hoglund R, Byakika Kibwika P, Lamorde M, Merry C, Ashton M, Hanpithakpong W, et al. Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications. Br J Clin Pharmacol. 2015;79:636-49 pubmed publisher

Rock B, Hengel S, Rock D, Wienkers L, Kunze K. Characterization of ritonavir-mediated inactivation of cytochrome P450 3A4. Mol Pharmacol. 2014;86:665-74 pubmed publisher

Corzo Martínez M, Mohan M, Dunlap J, Harte F. Effect of ultra-high pressure homogenization on the interaction between bovine casein micelles and ritonavir. Pharm Res. 2015;32:1055-71 pubmed publisher

Steiner K, Hagenbuch B, Dietrich D. Molecular cloning and functional characterization of a rainbow trout liver Oatp. Toxicol Appl Pharmacol. 2014;280:534-42 pubmed publisher

Khwitshana A, Greeff O, Hurrell T. Assessing adherence to the 2010 antiretroviral guidelines at the antiretroviral rollout clinic in 1 military hospital, South Africa: a retrospective, cross sectional study. S Afr Med J. 2014;104:495-500 pubmed publisher

Del Prete G, Shoemaker R, Oswald K, Lara A, Trubey C, Fast R, et al. Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected indian rhesus macaques. Antimicrob Agents Chemother. 2014;58:6790-806 pubmed publisher

Calderon M, Chairez C, Gordon L, Alfaro R, Kovacs J, Penzak S. Influence of Panax ginseng on the steady state pharmacokinetic profile of lopinavir-ritonavir in healthy volunteers. Pharmacotherapy. 2014;34:1151-8 pubmed publisher

Raffi F, Babiker A, Richert L, Molina J, George E, Antinori A, et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet. 2014;384:1942-51 pubmed publisher

Kuang C, Wang Y, Hu P, Gao F, Bu L, Wen X, et al. Ritonavir-induced hepatotoxicity and ultrastructural changes of hepatocytes. Ultrastruct Pathol. 2014;38:329-34 pubmed publisher

Powis K, Lockman S, Smeaton L, Hughes M, Fawzi W, Ogwu A, et al. Vitamin D insufficiency in HIV-infected pregnant women receiving antiretroviral therapy is not associated with morbidity, mortality or growth impairment in their uninfected infants in Botswana. Pediatr Infect Dis J. 2014;33:1141-7 pubmed publisher

Mai S, Lin L, Yang W, Deng X, Xie Z, Zong Y, et al. In vitro and in vivo release characteristics of Tacrolimus (FK506) from an episcleral drug-delivery implant. J Ocul Pharmacol Ther. 2014;30:670-80 pubmed publisher

Eyer K, Herger M, Krämer S, Dittrich P. Cell-free microfluidic determination of P-glycoprotein interactions with substrates and inhibitors. Pharm Res. 2014;31:3415-25 pubmed publisher

Bilello J, Lallos L, McCarville J, La Colla M, Serra I, Chapron C, et al. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus. Antimicrob Agents Chemother. 2014;58:4431-42 pubmed publisher

Pillai V, Parise R, Christner S, Rudek M, Beumer J, Venkataramanan R. Potential interactions between HIV drugs, ritonavir and efavirenz and anticancer drug, nilotinib--a study in primary cultures of human hepatocytes that is applicable to HIV patients with cancer. J Clin Pharmacol. 2014;54:1272-9 pubmed publisher

Yu C, Campbell S, Sponseller C, Small D, Medlock M, Morgan R. Steady-state pharmacokinetics of darunavir/ritonavir and pitavastatin when co-administered to healthy adult volunteers. Clin Drug Investig. 2014;34:475-82 pubmed publisher

Hendrikx J, Lagas J, Wagenaar E, Rosing H, Schellens J, Beijnen J, et al. Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation. Br J Cancer. 2014;110:2669-76 pubmed publisher